KR102320780B1 - Composition for relieving spinal pain and improving spinal flexibility and method for manufacturing the same - Google Patents
Composition for relieving spinal pain and improving spinal flexibility and method for manufacturing the same Download PDFInfo
- Publication number
- KR102320780B1 KR102320780B1 KR1020210013199A KR20210013199A KR102320780B1 KR 102320780 B1 KR102320780 B1 KR 102320780B1 KR 1020210013199 A KR1020210013199 A KR 1020210013199A KR 20210013199 A KR20210013199 A KR 20210013199A KR 102320780 B1 KR102320780 B1 KR 102320780B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- spinal
- present
- composition
- mixed
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 206010072005 Spinal pain Diseases 0.000 title abstract description 4
- 238000004519 manufacturing process Methods 0.000 title abstract description 4
- 238000000034 method Methods 0.000 title description 6
- RKFAZBXYICVSKP-AATRIKPKSA-N alpha-asarone Chemical compound COC1=CC(OC)=C(\C=C\C)C=C1OC RKFAZBXYICVSKP-AATRIKPKSA-N 0.000 claims abstract description 20
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 10
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims abstract description 10
- 102000012004 Ghrelin Human genes 0.000 claims abstract description 10
- 101800001586 Ghrelin Proteins 0.000 claims abstract description 10
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 claims abstract description 10
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 10
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 10
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims abstract description 10
- 229960001661 ursodiol Drugs 0.000 claims abstract description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 9
- 239000000284 extract Substances 0.000 claims description 112
- 239000000843 powder Substances 0.000 claims description 15
- 235000017945 Matricaria Nutrition 0.000 claims description 8
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 8
- 229940041514 candida albicans extract Drugs 0.000 claims description 8
- 235000020230 cinnamon extract Nutrition 0.000 claims description 8
- 235000013399 edible fruits Nutrition 0.000 claims description 8
- 229940023866 safflower seed extract Drugs 0.000 claims description 8
- 239000012138 yeast extract Substances 0.000 claims description 8
- 244000192528 Chrysanthemum parthenium Species 0.000 claims description 7
- 108010068370 Glutens Proteins 0.000 claims description 7
- 244000299461 Theobroma cacao Species 0.000 claims description 7
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 claims description 7
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 claims description 7
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims description 7
- 241001135917 Vitellaria paradoxa Species 0.000 claims description 7
- 229940038481 bee pollen Drugs 0.000 claims description 7
- 235000001046 cacaotero Nutrition 0.000 claims description 7
- 235000020708 ginger extract Nutrition 0.000 claims description 7
- 229940002508 ginger extract Drugs 0.000 claims description 7
- 235000021312 gluten Nutrition 0.000 claims description 7
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims description 7
- 235000019477 peppermint oil Nutrition 0.000 claims description 7
- 229940057910 shea butter Drugs 0.000 claims description 7
- 239000001827 citrus limon l. burm. f. peel extract Substances 0.000 claims description 6
- 229940092251 lemon peel extract Drugs 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 229920001285 xanthan gum Polymers 0.000 claims description 5
- 229940082509 xanthan gum Drugs 0.000 claims description 5
- 235000010493 xanthan gum Nutrition 0.000 claims description 5
- 239000000230 xanthan gum Substances 0.000 claims description 5
- 239000008213 purified water Substances 0.000 claims description 4
- 241000405911 Rehmannia glutinosa Species 0.000 claims description 3
- 230000032683 aging Effects 0.000 claims description 3
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 2
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 208000020339 Spinal injury Diseases 0.000 abstract description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 8
- 238000011084 recovery Methods 0.000 abstract description 8
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 235000013376 functional food Nutrition 0.000 description 34
- 230000036541 health Effects 0.000 description 34
- 238000002360 preparation method Methods 0.000 description 14
- 230000006872 improvement Effects 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 208000020431 spinal cord injury Diseases 0.000 description 7
- 238000010171 animal model Methods 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 210000000278 spinal cord Anatomy 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 208000008558 Osteophyte Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 241000405414 Rehmannia Species 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000005021 gait Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000007659 motor function Effects 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 235000014066 European mistletoe Nutrition 0.000 description 2
- 244000280244 Luffa acutangula Species 0.000 description 2
- 235000009814 Luffa aegyptiaca Nutrition 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 244000152640 Rhipsalis cassutha Species 0.000 description 2
- 235000012300 Rhipsalis cassutha Nutrition 0.000 description 2
- 240000006079 Schisandra chinensis Species 0.000 description 2
- 235000008422 Schisandra chinensis Nutrition 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 235000019206 astragalus extract Nutrition 0.000 description 2
- 238000009227 behaviour therapy Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229940067866 dandelion extract Drugs 0.000 description 2
- 235000020691 dandelion extract Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 229940094952 green tea extract Drugs 0.000 description 2
- 235000020688 green tea extract Nutrition 0.000 description 2
- 235000020721 horse chestnut extract Nutrition 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229940069774 quince extract Drugs 0.000 description 2
- 239000001845 taraxacum officinale leaf extract Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- 206010010214 Compression fracture Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 241000257465 Echinoidea Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- 208000007103 Spondylolisthesis Diseases 0.000 description 1
- 201000006490 Spondylolysis Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- -1 needles Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 206010039722 scoliosis Diseases 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000005198 spinal stenosis Diseases 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/306—Foods, ingredients or supplements having a functional effect on health having an effect on bone mass, e.g. osteoporosis prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/51—Polysaccharide
Abstract
Description
본 발명은 척추 통증 완화 및 척추 유연성 개선을 위한 조성물 및 이의 제조방법에 관한 것이다.The present invention relates to a composition for alleviating spinal pain and improving spinal flexibility and a method for preparing the same.
현대인의 생활 습관과 평균 수명의 증가로 인해 척추 손상 환자가 꾸준히 증가하고 있다. 척추 손상 발생 환자층은 오랜 시간 앉아서 컴퓨터를 통한 작업을 많이 하는 직장인뿐 아니라, 운동선수, 노약자, 가사 업무가 많은 중년 여성들과 같이 다양하게 분포되어 있다. 중추신경의 퇴화로 인한 운동 및 감각 기능이 손실되면 개인의 삶의 질이 현저히 저하되기 때문에, 척추 손상에 대한 치료방법과 약물 개발이 필요한 실정이다.Due to the lifestyle of modern people and the increase in life expectancy, the number of patients with spinal injuries is steadily increasing. The patients with spinal injuries are diversely distributed, such as not only office workers who sit for long periods of time and work on computers, but also athletes, the elderly, and middle-aged women who do a lot of housework. When motor and sensory functions are lost due to degeneration of the central nervous system, an individual's quality of life is significantly reduced. Therefore, there is a need for treatment methods and drug development for spinal injuries.
척추 손상은 주로 외상으로 인한 척추의 변위에 의하여 척수가 압박되면서 발생한다. 일차적인 손상과 함께 세포괴사가 일어나고 서행적으로 일어나는 세포자멸사에 의해 회백질의 신경세포와 백질의 희돌기교세포의 세포사멸을 유발하게 되고 축색돌기(axon)의 미엘린제거(demyelination)를 일으켜 궁극적으로 영구적인 기능장애를 발생하게 된다.Spinal injuries are mainly caused by compression of the spinal cord by displacement of the spine due to trauma. Cell necrosis occurs with primary damage, and apoptosis that occurs gradually causes apoptosis of gray matter neurons and white matter oligodendrocytes, and ultimately causes permanent demyelination of axons. functional impairment occurs.
이러한 척추 손상이 지속되거나 악화되면 허리, 등, 목에 있어서 통증이 수반되며, 앉아 있는 자세를 취하거나 물건을 들 때, 또는 격한 운동을 할 때 허리 통증을 느끼게 된다. 척추 통증 완화를 위해 종래에는 다양한 파스들을 사용하여 통증을 완화하고는 있으나 지속 시간이 길지 않고 척추 손상의 근본적인 원인을 해결하지 못한다는 어려움이 있다.If the spinal injury persists or worsens, pain in the lower back, back, and neck is accompanied, and lower back pain is felt when sitting, lifting objects, or performing vigorous exercise. In order to relieve pain in the spine, there is a difficulty in that the pain is relieved by using various pars in the prior art, but the duration is not long and the root cause of the damage to the spine is not solved.
이러한 배경하에서, 본 발명자들은 종래 척추 손상 치료용 약학 조성물보다 효과적이면서도 특이성이 높아 부작용 발생 가능성이 낮은 본 발명의 척추 손상 치료용 조성물을 발명하기에 이르렀다.Under this background, the present inventors came to invent a composition for treating spinal injury of the present invention, which is more effective and more specific than the conventional pharmaceutical composition for treating spinal injury, and has a low possibility of side effects.
본 발명은 파라옥시벤조산메틸, 그렐린, 우르소데옥시콜산, 알파 아사론 및 히알루론산을 포함하는, 척추 손상 질환의 예방 또는 개선용 건강기능식품 조성물을 제공하고자 한다.The present invention is to provide a health functional food composition for preventing or improving spinal injury diseases, including methyl paraoxybenzoate, ghrelin, ursodeoxycholic acid, alpha asarone and hyaluronic acid.
구체적으로, 본 발명은 초피나무열매추출물, 마트리카리아꽃추출물, 및 박하유를 추가로 포함하는, 척추 손상 질환의 예방 또는 개선용 건강기능식품 조성물을 제공하고자 한다.Specifically, the present invention is to provide a health functional food composition for the prevention or improvement of diseases of the spine, which further comprises a Chopi tree fruit extract, Matricaria flower extract, and peppermint oil.
구체적으로, 본 발명은 무환자 추출물, 지황 추출물, 복령 추출물, 벌화분 분말, 카카오나무 껍질 분말, 및 접골목 추출물을 추가로 포함하는, 척추 손상 질환의 예방 또는 개선용 건강기능식품 조성물을 제공하고자 한다.Specifically, the present invention is intended to provide a health functional food composition for preventing or improving spinal injury diseases, further comprising a patient-free extract, rehmannia extract, bokryeong extract, bee pollen powder, cacao bark powder, and osteophytes extract. .
구체적으로, 본 발명은 비수리 추출물, 한속단 추출물, 토사자 추출물, 사상자 추출물, 계피 추출물, 생강 추출물, 홍화씨 추출물, 및 마치현 추출물을 추가로 포함하는, 척추 손상 질환의 예방 또는 개선용 건강기능식품 조성물을 제공하고자 한다.Specifically, the present invention provides a health functional food composition for the prevention or improvement of spinal injury diseases, further comprising a non-suri extract, an extract of Hansokdan, a tosaja extract, a saengjae extract, a cinnamon extract, a ginger extract, a safflower seed extract, and an extract of mackerel. would like to provide
구체적으로, 본 발명은 쉐어버터, 글루텐 및 효모 추출물을 추가로 포함하는, 척추 손상 질환의 예방 또는 개선용 건강기능식품 조성물을 제공하고자 한다.Specifically, the present invention is to provide a health functional food composition for the prevention or improvement of spinal injury diseases, further comprising shea butter, gluten and yeast extract.
또한 본 발명은, 상기 척추 손상 질환의 예방 또는 개선용 건강기능식품 조성물의 제조방법을 제공하고자 한다.In addition, the present invention, to provide a method for preparing a health functional food composition for the prevention or improvement of the spinal injury disease.
본 발명의 상기 및 다른 목적과 이점은 바람직한 실시예를 설명한 하기의 설명으로부터 분명해질 것이다.These and other objects and advantages of the present invention will become apparent from the following description of preferred embodiments.
상기 목적은, 파라옥시벤조산메틸, 그렐린, 우르소데옥시콜산, 알파 아사론 및 히알루론산을 포함하는, 척추 손상 질환의 예방 또는 개선용 건강기능식품 조성물에 의해 달성될 수 있다.The above object, including methyl paraoxybenzoate, ghrelin, ursodeoxycholic acid, alpha asarone and hyaluronic acid, can be achieved by a health functional food composition for preventing or improving spinal injury diseases.
구체적으로, 초피나무열매추출물, 마트리카리아꽃추출물, 및 박하유를 추가로 포함하는, 척추 손상 질환의 예방 또는 개선용 건강기능식품 조성물일 수 있다.Specifically, it may be a health functional food composition for the prevention or improvement of spinal injury diseases, further comprising a Chopi tree fruit extract, a Matricaria flower extract, and peppermint oil.
구체적으로, 무환자 추출물, 지황 추출물, 복령 추출물, 벌화분 분말, 카카오나무 껍질 분말, 및 접골목 추출물을 추가로 포함하는, 척추 손상 질환의 예방 또는 개선용 건강기능식품 조성물일 수 있다.Specifically, it may be a health functional food composition for the prevention or improvement of a spinal injury disease, further comprising a patient-free extract, rehmannia extract, bokryeong extract, bee pollen powder, cacao bark powder, and osteophytes extract.
구체적으로, 비수리 추출물, 한속단 추출물, 토사자 추출물, 사상자 추출물, 계피 추출물, 생강 추출물, 홍화씨 추출물, 및 마치현 추출물을 추가로 포함하는, 척추 손상 질환의 예방 또는 개선용 건강기능식품 조성물일 수 있다.Specifically, it may be a health functional food composition for the prevention or improvement of a spinal injury disease, further comprising a non-suri extract, a Hansokdan extract, a tosaja extract, a casualty lice extract, a cinnamon extract, a ginger extract, a safflower seed extract, and a sea urchin extract.
구체적으로, 쉐어버터, 글루텐 및 효모 추출물을 추가로 포함하는, 척추 손상 질환의 예방 또는 개선용 건강기능식품 조성물일 수 있다.Specifically, it may be a health functional food composition for preventing or improving spinal injury diseases, further comprising shea butter, gluten and yeast extract.
또한, 상기 목적은 척추 손상 질환의 예방 또는 개선용 건강기능식품 조성물의 제조방법에 의해 달성될 수 있다.In addition, the above object can be achieved by a method for producing a health functional food composition for preventing or improving spinal injury disease.
본 발명에 따른 파라옥시벤조산메틸, 그렐린, 우르소데옥시콜산, 알파 아사론 및 히알루론산 등을 유효성분으로 포함하는 조성물은 척추 손상 모델에 투여시 운동 능력 회복효과가 우수하며, 약리 활성을 갖는 다양한 천연 유래 물질을 포함함으로써 척추 손상 질환에 대한 치료제로 활용이 가능하다.The composition comprising methyl paraoxybenzoate, ghrelin, ursodeoxycholic acid, alpha-asarone and hyaluronic acid according to the present invention as an active ingredient has excellent exercise ability recovery effect when administered to a spinal injury model, and has various pharmacological activities. By including a naturally-derived substance, it can be used as a treatment for spinal injury diseases.
다만, 본 발명의 효과들은 이상에서 언급한 효과로 제한되지 않으며, 언급되지 않은 또 다른 효과들은 아래의 기재로부터 당업자에게 명확하게 이해될 수 있을 것이다.However, the effects of the present invention are not limited to the above-mentioned effects, and other effects not mentioned will be clearly understood by those skilled in the art from the following description.
이하에서, 첨부된 도면을 참조하여 실시예들을 상세하게 설명한다. 그러나, 실시예들에는 다양한 변경이 가해질 수 있어서 특허출원의 권리 범위가 이러한 실시예들에 의해 제한되거나 한정되는 것은 아니다. 실시예들에 대한 모든 변경, 균등물 내지 대체물이 권리 범위에 포함되는 것으로 이해되어야 한다.Hereinafter, embodiments will be described in detail with reference to the accompanying drawings. However, since various changes may be made to the embodiments, the scope of the patent application is not limited or limited by these embodiments. It should be understood that all modifications, equivalents and substitutes for the embodiments are included in the scope of the rights.
실시예들에 대한 특정한 구조적 또는 기능적 설명들은 단지 예시를 위한 목적으로 개시된 것으로서, 다양한 형태로 변경되어 실시될 수 있다. 따라서, 실시예들은 특정한 개시형태로 한정되는 것이 아니며, 본 명세서의 범위는 기술적 사상에 포함되는 변경, 균등물, 또는 대체물을 포함한다.Specific structural or functional descriptions of the embodiments are disclosed for purposes of illustration only, and may be changed and implemented in various forms. Accordingly, the embodiments are not limited to a specific disclosure form, and the scope of the present specification includes changes, equivalents, or substitutes included in the technical spirit.
실시예에서 사용한 용어는 단지 설명을 목적으로 사용된 것으로, 한정하려는 의도로 해석되어서는 안된다. 단수의 표현은 문맥상 명백하게 다르게 뜻하지 않는 한, 복수의 표현을 포함한다. 본 명세서에서, "포함하다" 또는 "가지다" 등의 용어는 명세서 상에 기재된 특징, 숫자, 단계, 동작, 구성요소, 부품 또는 이들을 조합한 것이 존재함을 지정하려는 것이지, 하나 또는 그 이상의 다른 특징들이나 숫자, 단계, 동작, 구성요소, 부품 또는 이들을 조합한 것들의 존재 또는 부가 가능성을 미리 배제하지 않는 것으로 이해되어야 한다.The terms used in the examples are used for description purposes only, and should not be construed as limiting. The singular expression includes the plural expression unless the context clearly dictates otherwise. In the present specification, terms such as “comprise” or “have” are intended to designate that a feature, number, step, operation, component, part, or combination thereof described in the specification exists, but one or more other features It should be understood that this does not preclude the existence or addition of numbers, steps, operations, components, parts, or combinations thereof.
다르게 정의되지 않는 한, 기술적이거나 과학적인 용어를 포함해서 여기서 사용되는 모든 용어들은 실시예가 속하는 기술 분야에서 통상의 지식을 가진 자에 의해 일반적으로 이해되는 것과 동일한 의미를 가지고 있다. 일반적으로 사용되는 사전에 정의되어 있는 것과 같은 용어들은 관련 기술의 문맥 상 가지는 의미와 일치하는 의미를 가지는 것으로 해석되어야 하며, 본 출원에서 명백하게 정의하지 않는 한, 이상적이거나 과도하게 형식적인 의미로 해석되지 않는다.Unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art to which the embodiment belongs. Terms such as those defined in commonly used dictionaries should be interpreted as having a meaning consistent with the meaning in the context of the related art, and should not be interpreted in an ideal or excessively formal meaning unless explicitly defined in the present application. does not
본 발명의 이점 및 특징, 그리고 그것들을 달성하는 방법은 첨부되는 도면과 함께 상세하게 후술되어 있는 실시예들을 참조하면 명확해질 것이다. 그러나 본 발명은 이하에서 개시되는 실시예들에 한정되는 것이 아니라 서로 다른 다양한 형태로 구현될 것이며, 단지 본 실시예들은 본 발명의 개시가 완전하도록 하며, 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 발명의 범주를 완전하게 알려주기 위해 제공되는 것이며, 본 발명은 청구항의 범주에 의해 정의될 뿐이다.Advantages and features of the present invention and methods of achieving them will become apparent with reference to the embodiments described below in detail in conjunction with the accompanying drawings. However, the present invention is not limited to the embodiments disclosed below, but will be implemented in a variety of different forms, and only these embodiments allow the disclosure of the present invention to be complete, and common knowledge in the technical field to which the present invention belongs It is provided to fully inform the possessor of the scope of the invention, and the present invention is only defined by the scope of the claims.
본 발명의 실시예들에서, 별도로 다르게 정의되지 않는 한, 기술적이거나 과학적인 용어를 포함해서 여기서 사용되는 모든 용어들은 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에 의해 일반적으로 이해되는 것과 동일한 의미를 가지고 있다. 일반적으로 사용되는 사전에 정의되어 있는 것과 같은 용어들은 관련 기술의 문맥 상 가지는 의미와 일치하는 의미를 가지는 것으로 해석되어야 하며, 본 발명의 실시예에서 명백하게 정의하지 않는 한, 이상적이거나 과도하게 형식적인 의미로 해석되지 않는다.In the embodiments of the present invention, unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art to which the present invention belongs. have meaning Terms such as those defined in a commonly used dictionary should be interpreted as having a meaning consistent with the meaning in the context of the related art, and unless explicitly defined in an embodiment of the present invention, an ideal or excessively formal meaning is not interpreted as
본 발명의 실시예를 설명하기 위한 도면에 개시된 형상, 크기, 비율, 각도, 개수 등은 예시적인 것이므로 본 발명이 도시된 사항에 한정되는 것은 아니다. 또한, 본 발명을 설명함에 있어서, 관련된 공지 기술에 대한 구체적인 설명이 본 발명의 요지를 불필요하게 흐릴 수 있다고 판단되는 경우 그 상세한 설명은 생략한다. 본 명세서 상에서 언급된 ‘포함한다’, ‘갖는다’, ‘이루어진다’ 등이 사용되는 경우 ‘~만’이 사용되지 않는 이상 다른 부분이 추가될 수 있다. 구성 요소를 단수로 표현한 경우에 특별히 명시적인 기재 사항이 없는 한 복수를 포함하는 경우를 포함한다.The shapes, sizes, proportions, angles, numbers, etc. disclosed in the drawings for explaining the embodiments of the present invention are exemplary, and thus the present invention is not limited to the illustrated matters. In addition, in describing the present invention, if it is determined that a detailed description of a related known technology may unnecessarily obscure the subject matter of the present invention, the detailed description thereof will be omitted. When 'include', 'have', 'consist', etc. mentioned in this specification are used, other parts may be added unless 'only' is used. When a component is expressed in the singular, the case in which the plural is included is included unless otherwise explicitly stated.
구성 요소를 해석함에 있어서, 별도의 명시적 기재가 없더라도 오차 범위를 포함하는 것으로 해석한다.In interpreting the components, it is interpreted as including an error range even if there is no separate explicit description.
본 발명의 여러 실시예들의 각각 특징들이 부분적으로 또는 전체적으로 서로 결합 또는 조합 가능하며, 당업자가 충분히 이해할 수 있듯이 기술적으로 다양한 연동 및 구동이 가능하며, 각 실시예들이 서로에 대하여 독립적으로 실시 가능할 수도 있고 연관 관계로 함께 실시 가능할 수도 있다.Each feature of the various embodiments of the present invention may be partially or wholly combined or combined with each other, and technically various interlocking and driving are possible, as will be fully understood by those skilled in the art, and each embodiment may be independently implemented with respect to each other, It may be possible to implement together in a related relationship.
본원의 일 측면은, 파라옥시벤조산메틸, 그렐린, 우르소데옥시콜산, 알파 아사론 및 히알루론산을 포함하는, 척추 손상 질환의 예방 또는 개선용 건강기능식품 조성물을 제공한다.One aspect of the present application provides a health functional food composition for preventing or improving spinal injury diseases, including methyl paraoxybenzoate, ghrelin, ursodeoxycholic acid, alpha asarone and hyaluronic acid.
본 발명에 있어서, 상기 척추 손상 질환은 척추관 협착증, 허리 디스크, 목디스크, 퇴행성 디스크, 강직성 척추염, 척추압박골절, 디스크내장증, 척추분리증, 척추전방위증, 척추측만증 또는 좌골신경통인 것일 수 있다.In the present invention, the spinal injury disease may be spinal stenosis, lumbar disc, neck disc, degenerative disc, ankylosing spondylitis, vertebral compression fracture, bursitis, spondylolysis, spondylolisthesis, scoliosis, or sciatica.
본 발명에서 용어 “예방”이란 본 발명에 따른 조성물의 투여로 질환의 발병을 억제 또는 지연시키는 모든 행위를 말한다. 본 발명에서 용어 “개선”은 본 발명에 따른 조성물의 투여로 상기 질환의 증세가 호전되거나 이롭게 변경하는 모든 행위를 말한다.In the present invention, the term “prevention” refers to any action that suppresses or delays the onset of a disease by administration of the composition according to the present invention. In the present invention, the term “improvement” refers to any action in which the symptoms of the disease are improved or beneficially changed by administration of the composition according to the present invention.
본 발명의 식품 조성물은 일상적으로 섭취하는 것이 가능하기 때문에 척추 손상 질환의 예방 또는 개선 효과를 기대할 수 있어 매우 유용하다.Since the food composition of the present invention can be consumed on a daily basis, it is very useful because it can be expected to prevent or improve spinal injury diseases.
일 실시예에 있어서, 상기 조성물은 척추 통증 완화 및 척추 유연성 개선을 위한 것일 수 있다.In one embodiment, the composition may be for alleviating spinal pain and improving spinal flexibility.
일 실시예에 있어서, 상기 파라옥시벤조산메틸, 그렐린, 우르소데옥시콜산, 알파 아사론 및 히알루론산은 건강기능식품 조성물 전체 중량에 있어서 각각 0.1 내지 2, 1 내지 3, 0.1 내지 1, 3 내지 7, 2 내지 4 중량%로 포함되는 것일 수 있다.In one embodiment, the methyl paraoxybenzoate, ghrelin, ursodeoxycholic acid, alpha-asarone and hyaluronic acid are 0.1 to 2, 1 to 3, 0.1 to 1, 3 to 7, respectively, in the total weight of the health functional food composition , may be included in an amount of 2 to 4 wt%.
일 실시예에 있어서, 본 발명의 건강기능식품 조성물은 초피나무열매추출물, 마트리카리아꽃추출물, 및 박하유를 추가로 포함하는 것일 수 있다. In one embodiment, the health functional food composition of the present invention may be one that further comprises a Chopi tree fruit extract, a Matricaria flower extract, and peppermint oil.
일 실시예에 있어서, 상기 초피나무열매추출물, 마트리카리아꽃추출물, 및 박하유는 건강기능식품 조성물 전체 중량에 있어서 각각 4 내지 6, 4 내지 6, 1 내지 3 중량%로 포함되는 것일 수 있다.In one embodiment, the Chopi tree fruit extract, Matricaria flower extract, and peppermint oil may be included in an amount of 4 to 6, 4 to 6, and 1 to 3% by weight, respectively, based on the total weight of the health functional food composition.
일 실시예에 있어서, 본 발명의 건강기능식품 조성물은 무환자 추출물, 지황 추출물, 복령 추출물, 벌화분 분말, 카카오나무 껍질 분말, 및 접골목 추출물을 추가로 포함하는 것일 수 있다.In one embodiment, the health functional food composition of the present invention may be one that further comprises a patient-free extract, rehmannia extract, bokryeong extract, bee pollen powder, cacao bark powder, and extracts of osteophytes.
일 실시예에 있어서, 상기 무환자 추출물, 지황 추출물, 복령 추출물, 벌화분 분말, 카카오나무 껍질 분말, 및 접골목 추출물은 건강기능식품 조성물 전체 중량에 있어서 각각 2 내지 3, 1 내지 2, 0.1 내지 2, 0.1 내지 0.3, 0.1 내지 2, 3 내지 5 중량%로 포함되는 것일 수 있다.In one embodiment, the patient-free extract, rehubar extract, bokryeong extract, bee pollen powder, cacao bark powder, and osteoclast extract are 2 to 3, 1 to 2, 0.1 to 2, respectively, in the total weight of the health functional food composition , 0.1 to 0.3, 0.1 to 2, 3 to 5% by weight may be included.
일 실시예에 있어서, 본 발명의 건강기능식품 조성물은 비수리 추출물, 한속단 추출물, 토사자 추출물, 사상자 추출물, 계피 추출물, 생강 추출물, 홍화씨 추출물, 및 마치현 추출물을 추가로 포함하는 것일 수 있다.In one embodiment, the health functional food composition of the present invention may be one that further comprises a non-suri extract, an extract of Hansokdan, a tosaja extract, a saengsaeng extract, a cinnamon extract, a ginger extract, a safflower seed extract, and a horse chestnut extract.
일 실시예에 있어서, 상기 비수리 추출물, 한속단 추출물, 토사자 추출물, 사상자 추출물, 계피 추출물, 생강 추출물, 홍화씨 추출물, 및 마치현 추출물은 건강기능식품 조성물 전체 중량에 있어서 각각 2 내지 4 중량%로 포함되는 것일 수 있다.In one embodiment, the non-suri extract, Hansokdan extract, Tosaja extract, Sasangsaeng extract, cinnamon extract, ginger extract, safflower seed extract, and Machihyun extract are each contained in an amount of 2 to 4% by weight based on the total weight of the health functional food composition. it could be
일 실시예에 있어서, 본 발명의 건강기능식품 조성물은 오미자 추출물, 황기 추출물, 겨우살이 추출물, 모과 추출물, 수세미 추출물, 민들레 추출물 및 함초 추출물을 추가로 포함하는 것일 수 있다. In one embodiment, the health functional food composition of the present invention may be to further include Schisandra extract, Astragalus extract, mistletoe extract, quince extract, loofah extract, dandelion extract, and green tea extract.
일 실시예에 있어서, 상기 오미자 추출물, 황기 추출물, 겨우살이 추출물, 모과 추출물, 수세미 추출물, 민들레 추출물 및 함초 추출물은 건강기능식품 조성물 전체 중량에 있어서 각각 1 내지 3 중량%로 포함되는 것일 수 있다.In one embodiment, the Schisandra extract, Astragalus extract, mistletoe extract, quince extract, loofah extract, dandelion extract and green tea extract may be included in an amount of 1 to 3% by weight, respectively, based on the total weight of the health functional food composition.
일 실시예에 있어서, 본 발명의 건강기능식품 조성물은 레몬 껍질 추출물 및 잔탄검을 추가로 포함하는 것일 수 있다.In one embodiment, the health functional food composition of the present invention may further include a lemon peel extract and xanthan gum.
일 실시예에 있어서, 상기 레몬 껍질 추출물 및 잔탄검은 건강기능식품 조성물 전체 중량에 있어서 각각 5, 0.5 중량%로 포함되는 것일 수 있다.In one embodiment, the lemon peel extract and xanthan gum may be included in an amount of 5 and 0.5% by weight, respectively, based on the total weight of the health functional food composition.
일 실시예에 있어서, 본 발명의 건강기능식품 조성물은 쉐어버터, 글루텐 및 효모 추출물을 추가로 포함하는 것일 수 있다.In one embodiment, the health functional food composition of the present invention may be to further include shea butter, gluten and yeast extract.
일 실시예에 있어서, 상기 쉐어버터, 글루텐 및 효모 추출물은 건강기능식품 조성물 전체 중량에 있어서 각각 0.2, 0.05, 5 중량%로 포함되는 것일 수 있다.In one embodiment, the shea butter, gluten and yeast extract may be included in each of 0.2, 0.05, and 5% by weight based on the total weight of the health functional food composition.
본 발명의 식품 조성물은 환제, 분말, 과립, 침제, 정제, 캡슐 또는 액제 등의 형태를 포함하며, 본 발명의 조성물을 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 예를 들어, 음료, 껌, 차, 비타민 복합제, 건강보조 식품류 등이 있다.The food composition of the present invention includes the form of pills, powders, granules, needles, tablets, capsules or liquids, and the food to which the composition of the present invention can be added, for example, various foods, for example, There are beverages, gum, tea, vitamin complexes, and health supplements.
본 발명의 식품 조성물에서 포함할 수 있는 필수 성분으로 상기 유효물질을 포함하는 척수 손상 질환 예방 및 치료 활성을 갖는 조성물 또는 그의 유효 성분, 또는 그의 생리학적으로 허용 가능한 염을 함유하는 외에는 다른 성분에는 특별히 제한이 없으며 통상의 식품과 같이 여러가지 생약추출물, 식품 보조 첨가제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다.As an essential ingredient that can be included in the food composition of the present invention, a composition having a preventive and therapeutic activity for spinal cord injury disease comprising the active substance, or an active ingredient thereof, or other ingredients except containing a physiologically acceptable salt thereof There is no limitation, and it may contain various herbal extracts, food supplement additives, natural carbohydrates, etc. as additional ingredients like normal food.
본 발명의 다른 일 측면은, 척추 손상 질환의 예방 또는 개선용 건강기능식품 조성물의 제조방법을 제공한다.Another aspect of the present invention provides a method for preparing a health functional food composition for preventing or improving spinal injury diseases.
상기 건강기능식품 조성물의 제조방법은 초피나무열매추출물, 마트리카리아꽃추출물, 무환자 추출물, 지황 추출물, 복령 추출물, 접골목 추출물, 비수리 추출물, 한속단 추출물, 토사자 추출물, 사상자 추출물, 계피 추출물, 생강 추출물, 홍화씨 추출물, 및 마치현 추출물을 혼합하여 제1 혼합 추출물을 제조하는 단계; 쉐어버터, 레몬 껍질 추출물, 잔탄검, 글루텐, 벌화분 분말, 카카오나무 껍질 분말을 혼합하여 제2 혼합 추출물을 제조하는 단계; 제2 혼합 추출물에 효모 추출물 및 정제수를 첨가한 후 35~40℃ 온도에서 12시간 동안 숙성시키는 단계; 상기 숙성된 제2 혼합 추출물과 제1 혼합 추출물을 혼합하는 단계; 상기 혼합물에 파라옥시벤조산메틸, 그렐린, 우르소데옥시콜산, 알파 아사론 및 히알루론산을 첨가하여 혼합하는 단계; 가열 및 건조를 통해 수분을 증발시켜 고형화 또는 젤화 시키는 단계; 및 상기 고형화 또는 젤화된 조성물에 박하유를 도포하는 단계를 포함한다.The manufacturing method of the health functional food composition is a chopi tree fruit extract, a matricaria flower extract, a patient-free extract, a rhubarb extract, a bokryeong extract, an ethmoid extract, a non-suri extract, a hansokdan extract, a tosaja extract, a casualty extract, a cinnamon extract, a ginger Preparing a first mixed extract by mixing the extract, the safflower seed extract, and the extract of Machihyun; preparing a second mixed extract by mixing shea butter, lemon peel extract, xanthan gum, gluten, bee pollen powder, and cacao bark powder; After adding yeast extract and purified water to the second mixed extract, aging at a temperature of 35-40° C. for 12 hours; mixing the aged second mixed extract and the first mixed extract; adding and mixing methyl paraoxybenzoate, ghrelin, ursodeoxycholic acid, alpha-asarone and hyaluronic acid to the mixture; evaporating moisture through heating and drying to solidify or gel; and applying peppermint oil to the solidified or gelled composition.
상기 건강기능식품 조성물에 대해서는 전술한 바와 같다.The health functional food composition is as described above.
이하, 구체적인 실시예와 비교예를 통하여 본 발명의 구성 및 그에 따른 효과를 보다 상세히 설명하고자 한다. 그러나, 본 실시예는 본 발명을 보다 구체적으로 설명하기 위한 것이며, 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.Hereinafter, the configuration of the present invention and its effects will be described in more detail through specific examples and comparative examples. However, these examples are for explaining the present invention in more detail, and the scope of the present invention is not limited to these examples.
제조예 1: 척추 손상 질환의 예방 또는 개선용 건강기능식품의 제조Preparation Example 1: Preparation of health functional food for preventing or improving spinal injury disease
척추 손상 질환의 예방 또는 개선용 건강기능식품 조성물을 제조하였다. 구체적으로, 식물 또는 약재 추출물로서 초피나무열매추출물, 마트리카리아꽃추출물, 무환자 추출물, 지황 추출물, 복령 추출물, 접골목 추출물, 비수리 추출물, 한속단 추출물, 토사자 추출물, 사상자 추출물, 계피 추출물, 생강 추출물, 홍화씨 추출물, 마치현 추출물, 레몬 껍질 추출물을 제조하였으며, 각각의 추출물은 고형분 300g에 정제수 5L를 이용하여 열수 추출하였다.A health functional food composition for preventing or improving spinal injury was prepared. Specifically, as a plant or medicinal extract, the extract of Chopi tree fruit, Matricaria flower extract, non-patient extract, Rehmannia glutinosa extract, bokryeong extract, chrysanthemum extract, non-suri extract, Hansokdan extract, Tosaja extract, casualty extract, cinnamon extract, ginger extract , safflower seed extract, horse chestnut extract, and lemon peel extract were prepared, and each extract was extracted with hot water using 5L of purified water at 300 g of solid content.
먼저, 제1 혼합 추출물로서 초피나무열매추출물, 마트리카리아꽃추출물, 무환자 추출물, 지황 추출물, 복령 추출물, 접골목 추출물, 비수리 추출물, 한속단 추출물, 토사자 추출물, 사상자 추출물, 계피 추출물, 생강 추출물, 홍화씨 추출물, 및 마치현 추출물을 각각 50g, 50g, 25g, 15g, 1g, 40g, 30g, 30g, 30g, 30g, 30g, 30g, 30g, 30g, 30g으로 첨가하여 혼합하였다.First, as the first mixed extract, Chopi tree fruit extract, Matricaria flower extract, non-patient extract, Rehmannia glutinosa extract, Bokryeong extract, Colchulum extract, Bisuri extract, Hansokdan extract, Tosaja extract, Casualty extract, Cinnamon extract, Ginger extract, The safflower seed extract and the extract of Machisinosa were added at 50 g, 50 g, 25 g, 15 g, 1 g, 40 g, 30 g, 30 g, 30 g, 30 g, 30 g, 30 g, 30 g, 30 g, and 30 g, respectively, and mixed.
다음으로 제2 혼합 추출물로서, 쉐어버터, 레몬 껍질 추출물, 잔탄검, 글루텐, 벌화분 분말, 카카오나무 껍질 분말을 각각 2g, 50g, 5g, 0.5g, 2g, 10g 첨가하여 혼합하였다. 상기 제2 혼합 추출물에 효모 추출물 50g, 정제수 200g을 첨가하고, 37℃ 온도에서 유지하여 12시간 동안 숙성, 발효시켰다.Next, as the second mixed extract, shea butter, lemon peel extract, xanthan gum, gluten, bee pollen powder, and cacao bark powder were added and mixed with 2 g, 50 g, 5 g, 0.5 g, 2 g, and 10 g, respectively. 50 g of yeast extract and 200 g of purified water were added to the second mixed extract, and the mixture was aged and fermented for 12 hours at 37°C.
이후 숙성된 제2 혼합 추출물과 제1 혼합 추출물을 혼합하고, 파라옥시벤조산메틸, 그렐린, 우르소데옥시콜산, 알파 아사론 및 히알루론산을 각각 10g, 20g, 5g, 50g, 30g, 첨가하여 혼합하였다. 혼합된 조성물을 건조기에서 가열하여 수분을 증발시켰고, 유동성이 있는 고형화 젤 형태의 조성물에 박하유 20g을 얇게 도포하여 코팅함으로써 제조예 1의 건강기능식품 조성물을 완성하였다.Then, the aged second mixed extract and the first mixed extract were mixed, and methyl paraoxybenzoate, ghrelin, ursodeoxycholic acid, alpha-asarone and hyaluronic acid were added and mixed with 10 g, 20 g, 5 g, 50 g, 30 g, respectively. . The mixed composition was heated in a dryer to evaporate moisture, and 20 g of peppermint oil was thinly applied to the composition in the form of a fluidized solidified gel and coated, thereby completing the health functional food composition of Preparation Example 1.
한편 상기 제조예 1과 동일한 방법으로 제조하되, 제2 혼합추출물에 효모 추출물을 첨가하여 숙성하는 단계를 제외한 제조예 2의 조성물, 제1 혼합추출물의 첨가 없이 제조한 제조예 3의 조성물, 파라옥시벤조산메틸, 그렐린, 우르소데옥시콜산, 알파 아사론 및 히알루론산을 첨가하지 않은 제조예 4의 조성물을 비교예로 제조하였다.Meanwhile, prepared in the same manner as in Preparation Example 1, except for the step of aging by adding a yeast extract to the second mixed extract, the composition of Preparation Example 2, the composition of Preparation Example 3 prepared without the addition of the first mixed extract, paraoxy The composition of Preparation Example 4 without addition of methyl benzoate, ghrelin, ursodeoxycholic acid, alpha-asarone and hyaluronic acid was prepared as a comparative example.
실험예 1: 척수 손상 동물 모델에서의 효과 확인Experimental Example 1: Confirmation of effect in spinal cord injury animal model
1-1. 척수손상 동물 모델 제작1-1. Creation of an animal model for spinal cord injury
척수손상 동물모델은 총 20마리를 제작하였고, 체중이 180 내지 200g인 수컷 스프라그 돌리 래트(adult male Sprague-Dawley rats)를 사용하였으며, 마취 후 후굴절제술로서 척수를 노출시키고 전용 포셉(self-closed forceps, Germany)을 사용하여 10초간 척수를 압박시킴으로써 척수를 손상 시킨 후, 근육과 피부를 봉합하였다.A total of 20 spinal cord injury animal models were produced, and adult male Sprague-Dawley rats weighing 180 to 200 g were used. After anesthesia, the spinal cord was exposed as postrefractive refraction and dedicated forceps (self-closed). Forceps, Germany) were used to compress the spinal cord for 10 sec. After injuring the spinal cord, the muscles and skin were sutured.
1-2. 척수손상 모델의 약학 조성물 투여 및 행동 반응 검사1-2. Pharmaceutical composition administration and behavioral response test in spinal cord injury model
실험동물관리와 연구지침은 국제실험동물관리평가인증협회(AAALAC)의 지침을 준수하였다. 척수손상 동물모델 전체 20마리를 각각 5마리씩 4개의 군으로 나누어, 제조예 1 내지 4의 건강기능식품 조성물을 20g씩 사료에 섞어 1일 1회로 5일간 제공하였다.Laboratory animal management and research guidelines complied with the guidelines of the International Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). A total of 20 spinal cord injury animal models were divided into 4 groups of 5 each, and 20 g of the health functional food composition of Preparation Examples 1 to 4 was mixed with the feed and provided once a day for 5 days.
운동기능 검사는 조성물의 제공이 종료된 후 2일간 총 4회를 시행하였으며, Basso-Beattie-Bresnahan(BBB)를 사용하여 동물의 뒷다리 기능 회복을 검사하였다. BBB의 척도는 총 21점으로 나누어져 있으며 크게 3단계로 나뉜다. 첫번째 회복 단계에서는 관절의 움직임의 크기와 발바닥이 바닥에 닿는지의 여부를 확인하였고, 두 번째 회복단계에서는 체중을 실은 걸음의 회복 정도를 확인하였며, 마지막 단계에서는 걸음걸이의 조화와 꼬리의 회복 상태를 관찰하였다.The motor function test was performed a total of 4 times for 2 days after the provision of the composition was finished, and the recovery of the hind limb function of the animal was tested using Basso-Beattie-Bresnahan (BBB). The BBB scale is divided into a total of 21 points and is divided into three stages. In the first recovery stage, the magnitude of joint movement and whether the soles of the feet touch the floor were checked. In the second recovery stage, the recovery level of the weight-bearing gait was confirmed. In the last stage, gait harmony and tail recovery status was observed.
1-3. Basso-Beattie-Bresnahan(BBB) 운동기능 평가를 이용한 신경기능 회복 효과 확인1-3. Confirmation of nerve function recovery effect using Basso-Beattie-Bresnahan (BBB) motor function evaluation
상기 실시예 1-2와 같이, 척수손상 흰쥐에 건강기능식품 조성물을 투여 후 Basso- Beattie- Bresnahan(BBB) 운동기능 평가 방식(locomotor rating system)을 이용하여 행동검사를 진행하였다. 행동 검사 결과는 BBB Score로 표기하였다.As in Example 1-2, a behavioral test was performed using the Basso- Beattie- Bresnahan (BBB) locomotor rating system after administration of the health functional food composition to the rats with spinal cord injury. Behavioral test results were expressed as BBB Score.
그 결과, 제조예 2 내지 4의 조성물을 제공받은 마우스는 체중을 실지 못한 걸음을 걸어 10점 이하의 BBB 점수를 나타낸 반면, 제조예 1의 조성물을 제공받은 마우스 군은 체중을 실어 걸음으로써 10점 이상의 점수를 나타내었으며 걸음걸이의 조화를 보이며 행동기능이 회복되었음을 보였다. 또한 BBB 점수가 유의하게 회복되었음을 확인하였다.As a result, the mice receiving the composition of Preparation Examples 2 to 4 showed a BBB score of 10 or less by walking without weight, whereas the group of mice receiving the composition of Preparation Example 1 took 10 points by walking with their body weight. It showed the above score, showed gait harmony, and behavioral function was restored. In addition, it was confirmed that the BBB score was significantly recovered.
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
이상 본 발명의 실시예들을 더욱 상세하게 설명하였으나, 본 발명은 반드시 이러한 실시예로 국한되는 것은 아니고, 본 발명의 기술사상을 벗어나지 않는 범위 내에서 다양하게 변형 실시될 수 있다. 따라서, 본 발명에 개시된 실시예들은 본 발명의 기술 사상을 한정하기 위한 것이 아니라 설명하기 위한 것이고, 이러한 실시예에 의하여 본 발명의 기술 사상의 범위가 한정되는 것은 아니다. 그러므로, 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야만 한다. 본 발명의 보호 범위는 아래의 청구범위에 의하여 해석되어야 하며, 그와 동등한 범위 내에 있는 모든 기술 사상은 본 발명의 권리범위에 포함되는 것으로 해석되어야 할 것이다.Although the embodiments of the present invention have been described in more detail above, the present invention is not necessarily limited to these embodiments, and various modifications may be made without departing from the technical spirit of the present invention. Therefore, the embodiments disclosed in the present invention are not intended to limit the technical spirit of the present invention, but to explain, and the scope of the technical spirit of the present invention is not limited by these embodiments. Therefore, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. The protection scope of the present invention should be construed by the following claims, and all technical ideas within the equivalent range should be construed as being included in the scope of the present invention.
그러므로, 다른 구현들, 다른 실시예들 및 특허청구범위와 균등한 것들도 후술하는 청구범위의 범위에 속한다.Therefore, other implementations, other embodiments, and equivalents to the claims are also within the scope of the following claims.
Claims (3)
Chopi tree fruit extract, Matricaria flower extract, non-patient extract, Rehmannia glutinosa extract, Bokryeong extract, chrysanthemum extract, Bisuri extract, Hansokdan extract, Tosaja extract, Caesarean extract, Cinnamon extract, Ginger extract, Safflower seed extract, and Machihyun extract mixing to prepare a first mixed extract; preparing a second mixed extract by mixing shea butter, lemon peel extract, xanthan gum, gluten, bee pollen powder, and cacao bark powder; After adding yeast extract and purified water to the second mixed extract, aging at a temperature of 35-40° C. for 12 hours; mixing the aged second mixed extract and the first mixed extract; adding and mixing methyl paraoxybenzoate, ghrelin, ursodeoxycholic acid, alpha-asarone and hyaluronic acid to the mixture; evaporating moisture through heating and drying to solidify or gel; and applying peppermint oil to the solidified or gelled composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210013199A KR102320780B1 (en) | 2021-01-29 | 2021-01-29 | Composition for relieving spinal pain and improving spinal flexibility and method for manufacturing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210013199A KR102320780B1 (en) | 2021-01-29 | 2021-01-29 | Composition for relieving spinal pain and improving spinal flexibility and method for manufacturing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR102320780B1 true KR102320780B1 (en) | 2021-11-02 |
Family
ID=78476215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210013199A KR102320780B1 (en) | 2021-01-29 | 2021-01-29 | Composition for relieving spinal pain and improving spinal flexibility and method for manufacturing the same |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102320780B1 (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060006004A (en) | 2003-02-24 | 2006-01-18 | 각고호우징 게이오기주크 | Remedy for spinal injury containing interleukin-6 antagonist |
| KR20070018015A (en) | 2004-03-25 | 2007-02-13 | 돔페 파르마 에스.피.에이. | Use of n-2-aryl-propionyl-sulfonamides for the treatment of spinal cord injury |
| KR20090076254A (en) * | 2008-01-08 | 2009-07-13 | 경희대학교 산학협력단 | Pharmaceutical composition comprising the ghrelin for treating injury of spinal cord |
| KR20190009174A (en) * | 2017-07-18 | 2019-01-28 | 의료법인 성광의료재단 | Composition for preventing or treating inflammatory diseases or spinal cord injury comprising ursodeoxycholic acid |
| KR101970099B1 (en) | 2018-02-07 | 2019-04-17 | 한국과학기술연구원 | A composition for preventing and treating spinal cord injury |
| KR20190040409A (en) * | 2017-10-10 | 2019-04-18 | 의료법인 성광의료재단 | Composition for preventing or treating spinal cord injury comprising α-asarone |
-
2021
- 2021-01-29 KR KR1020210013199A patent/KR102320780B1/en active IP Right Grant
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060006004A (en) | 2003-02-24 | 2006-01-18 | 각고호우징 게이오기주크 | Remedy for spinal injury containing interleukin-6 antagonist |
| KR20070018015A (en) | 2004-03-25 | 2007-02-13 | 돔페 파르마 에스.피.에이. | Use of n-2-aryl-propionyl-sulfonamides for the treatment of spinal cord injury |
| KR20090076254A (en) * | 2008-01-08 | 2009-07-13 | 경희대학교 산학협력단 | Pharmaceutical composition comprising the ghrelin for treating injury of spinal cord |
| KR20190009174A (en) * | 2017-07-18 | 2019-01-28 | 의료법인 성광의료재단 | Composition for preventing or treating inflammatory diseases or spinal cord injury comprising ursodeoxycholic acid |
| KR20190040409A (en) * | 2017-10-10 | 2019-04-18 | 의료법인 성광의료재단 | Composition for preventing or treating spinal cord injury comprising α-asarone |
| KR101970099B1 (en) | 2018-02-07 | 2019-04-17 | 한국과학기술연구원 | A composition for preventing and treating spinal cord injury |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Priya et al. | Phyllanthus emblica Linn.(Amla)—a natural gift to humans: an overview | |
| CN1408397A (en) | Composition containing melatonin and galangal fruit traditional Chinese medicine | |
| KR100743205B1 (en) | Anti-atopic cosmetic composition | |
| CN110960624A (en) | Anti-fatigue composition and preparation method thereof | |
| CN104225417A (en) | Traditional Chinese medicine composition with function of assisting improvement of memory and preparation method thereof | |
| KR101565159B1 (en) | Compositions for preventing or treating aging and arthritis | |
| CN100525817C (en) | Medicinal composition for treating tuberculosis and its preparing process | |
| KR102320780B1 (en) | Composition for relieving spinal pain and improving spinal flexibility and method for manufacturing the same | |
| KR20150033797A (en) | Pharmaceutical composition for prevention and treatment of atopic skin disease | |
| JP2006514041A (en) | Composition for suppressing obesity using mixed herbal materials | |
| CN102526444A (en) | Traditional Chinese medicine composition for invigorating kidney and strengthening yang and preparation method thereof | |
| CN106177166A (en) | A kind of compositions with function of physical fatigue alleviation and preparation method thereof | |
| JP2958198B2 (en) | Analgesic pharmaceutical composition | |
| KR20100012913A (en) | Compositions for topical treatment of arthritis | |
| CN101244246A (en) | Chinese medicine composition for treating epilepsy and method of preparing the same | |
| KR101511699B1 (en) | Composition for improving atopic dermatitis containing mineral water | |
| KR20140143952A (en) | Arthritis Remedy Composition and manufacture method having immunity and the circulation of the blood improvement fuction | |
| CN1416884A (en) | Melatonin composition with soporific effect and its prepn | |
| RU2452507C1 (en) | Phytotranquiliser | |
| KR20190101632A (en) | Anti-inflammatory composition containing medicinal herbs | |
| JP6710408B2 (en) | Composition containing black ginger extract | |
| KR102482128B1 (en) | Compositions containing new methylsulfonylmethane(MSM) with increased arthritis treatment effect and the process of manufacture thereof | |
| KR102492549B1 (en) | Composition comprising collagen peptides and herbal extracts for preventing and improving anemia | |
| CN102370837A (en) | Kidney-invigorating and tendon-reinforcing capsule | |
| KR102143401B1 (en) | patch composition including natural component and patch manufacturing method using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |